Challenges of Treating a Patient With Advanced Prostate Cancer During the COVID-19 Pandemic.
Identifieur interne : 000825 ( Main/Exploration ); précédent : 000824; suivant : 000826Challenges of Treating a Patient With Advanced Prostate Cancer During the COVID-19 Pandemic.
Auteurs : Lucil Carril-Ajuria [Espagne] ; Yuly A. Remolina-Bonilla [Mexique] ; Alberto Carretero-Gonzalez [Espagne] ; Maricruz Martin-Soberon [Espagne] ; Daniel Castellano [Espagne] ; Christianne Bourlon [Mexique] ; Guillermo De Velasco [Espagne] ; Maria T. Bourlon [Mexique]Source :
- Oncology (Williston Park, N.Y.) [ 0890-9091 ] ; 2020.
Descripteurs français
- KwdFr :
- Acide zolédronique (usage thérapeutique), Agents de maintien de la densité osseuse (usage thérapeutique), Androstènes (usage thérapeutique), Antagonistes des androgènes (usage thérapeutique), Anticoagulants (usage thérapeutique), Antinéoplasiques (usage thérapeutique), Association médicamenteuse (MeSH), Betacoronavirus (MeSH), Docetaxel (usage thérapeutique), Douleur cancéreuse (complications), Douleur cancéreuse (thérapie), Détermination de l'admissibilité (MeSH), Humains (MeSH), Héparine bas poids moléculaire (usage thérapeutique), Indice de gravité de la maladie (MeSH), Infections à coronavirus (complications), Infections à coronavirus (thérapie), Insuffisance respiratoire (thérapie), Insuffisance respiratoire (étiologie), Insuffisance rénale (MeSH), Lopinavir (usage thérapeutique), Mâle (MeSH), Oxygénothérapie (MeSH), Pandémies (MeSH), Pneumopathie virale (complications), Pneumopathie virale (thérapie), RT-PCR (MeSH), Ritonavir (usage thérapeutique), Soins palliatifs (MeSH), Sujet âgé (MeSH), Tumeurs osseuses (complications), Tumeurs osseuses (secondaire), Tumeurs osseuses (traitement médicamenteux), Tumeurs prostatiques résistantes à la castration (anatomopathologie), Tumeurs prostatiques résistantes à la castration (complications), Tumeurs prostatiques résistantes à la castration (traitement médicamenteux), Unités de soins intensifs (ressources et distribution), Évolution de la maladie (MeSH).
- MESH :
- anatomopathologie : Tumeurs prostatiques résistantes à la castration.
- ressources et distribution : Unités de soins intensifs.
- secondaire : Tumeurs osseuses.
- thérapie : Douleur cancéreuse, Infections à coronavirus, Insuffisance respiratoire, Pneumopathie virale.
- traitement médicamenteux : Tumeurs osseuses, Tumeurs prostatiques résistantes à la castration.
- usage thérapeutique : Acide zolédronique, Agents de maintien de la densité osseuse, Androstènes, Antagonistes des androgènes, Anticoagulants, Antinéoplasiques, Docetaxel, Douleur cancéreuse, Héparine bas poids moléculaire, Infections à coronavirus, Lopinavir, Pneumopathie virale, Ritonavir, Tumeurs osseuses, Tumeurs prostatiques résistantes à la castration.
- étiologie : Insuffisance respiratoire.
- Association médicamenteuse, Betacoronavirus, Détermination de l'admissibilité, Humains, Indice de gravité de la maladie, Insuffisance rénale, Mâle, Oxygénothérapie, Pandémies, RT-PCR, Soins palliatifs, Sujet âgé, Évolution de la maladie.
English descriptors
- KwdEn :
- Aged (MeSH), Androgen Antagonists (therapeutic use), Androstenes (therapeutic use), Anticoagulants (therapeutic use), Antineoplastic Agents (therapeutic use), Betacoronavirus (MeSH), Bone Density Conservation Agents (therapeutic use), Bone Neoplasms (complications), Bone Neoplasms (drug therapy), Bone Neoplasms (secondary), Cancer Pain (complications), Cancer Pain (therapy), Coronavirus Infections (complications), Coronavirus Infections (therapy), Disease Progression (MeSH), Docetaxel (therapeutic use), Drug Combinations (MeSH), Eligibility Determination (MeSH), Heparin, Low-Molecular-Weight (therapeutic use), Humans (MeSH), Intensive Care Units (supply & distribution), Lopinavir (therapeutic use), Male (MeSH), Oxygen Inhalation Therapy (MeSH), Palliative Care (MeSH), Pandemics (MeSH), Pneumonia, Viral (complications), Pneumonia, Viral (therapy), Prostatic Neoplasms, Castration-Resistant (complications), Prostatic Neoplasms, Castration-Resistant (drug therapy), Prostatic Neoplasms, Castration-Resistant (pathology), Renal Insufficiency (MeSH), Respiratory Insufficiency (etiology), Respiratory Insufficiency (therapy), Reverse Transcriptase Polymerase Chain Reaction (MeSH), Ritonavir (therapeutic use), Severity of Illness Index (MeSH), Zoledronic Acid (therapeutic use).
- MESH :
- chemical , therapeutic use : Androgen Antagonists, Androstenes, Anticoagulants, Antineoplastic Agents, Bone Density Conservation Agents, Docetaxel, Heparin, Low-Molecular-Weight, Lopinavir, Ritonavir, Zoledronic Acid.
- complications : Bone Neoplasms, Cancer Pain, Coronavirus Infections, Pneumonia, Viral, Prostatic Neoplasms, Castration-Resistant.
- drug therapy : Bone Neoplasms, Prostatic Neoplasms, Castration-Resistant.
- etiology : Respiratory Insufficiency.
- pathology : Prostatic Neoplasms, Castration-Resistant.
- secondary : Bone Neoplasms.
- supply & distribution : Intensive Care Units.
- therapy : Cancer Pain, Coronavirus Infections, Pneumonia, Viral, Respiratory Insufficiency.
- Aged, Betacoronavirus, Disease Progression, Drug Combinations, Eligibility Determination, Humans, Male, Oxygen Inhalation Therapy, Palliative Care, Pandemics, Renal Insufficiency, Reverse Transcriptase Polymerase Chain Reaction, Severity of Illness Index.
Abstract
A 78-year-old man had a medical history of hypertension, atrial fibrillation, chronic kidney disease, and metastatic castration-resistant prostate cancer (CRPC). He had progressed to first-line therapy for CRPC with abiraterone plus androgen-deprivation therapy (ADT) and as second-line therapy he was being treated with docetaxel, with biochemical progression in his last prostate specific antigen measurement. He was admitted to the hospital on April 2020, in the middle of the coronavirus disease 2019 (COVID-19) pandemic, because of painful bone lesions and deterioration of renal function.
DOI: 10.46883/ONC.2020.3408.0317
PubMed: 32785928
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Challenges of Treating a Patient With Advanced Prostate Cancer During the COVID-19 Pandemic.</title><author><name sortKey="Carril Ajuria, Lucil" sort="Carril Ajuria, Lucil" uniqKey="Carril Ajuria L" first="Lucil" last="Carril-Ajuria">Lucil Carril-Ajuria</name><affiliation wicri:level="3"><nlm:affiliation>Department of Medical Oncology, Hospital Universitario 12 de Octubre, Madrid, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Department of Medical Oncology, Hospital Universitario 12 de Octubre, Madrid</wicri:regionArea><placeName><settlement type="city">Madrid</settlement><region nuts="2" type="region">Communauté de Madrid</region></placeName></affiliation></author><author><name sortKey="Remolina Bonilla, Yuly A" sort="Remolina Bonilla, Yuly A" uniqKey="Remolina Bonilla Y" first="Yuly A" last="Remolina-Bonilla">Yuly A. Remolina-Bonilla</name><affiliation wicri:level="1"><nlm:affiliation>Department of Hematology and Oncology, Instituto Nacional de Ciencias Medicas y Nutrición Salvador Zubirán, Mexico City, Mexico.</nlm:affiliation><country xml:lang="fr">Mexique</country><wicri:regionArea>Department of Hematology and Oncology, Instituto Nacional de Ciencias Medicas y Nutrición Salvador Zubirán, Mexico City</wicri:regionArea><wicri:noRegion>Mexico City</wicri:noRegion></affiliation></author><author><name sortKey="Carretero Gonzalez, Alberto" sort="Carretero Gonzalez, Alberto" uniqKey="Carretero Gonzalez A" first="Alberto" last="Carretero-Gonzalez">Alberto Carretero-Gonzalez</name><affiliation wicri:level="3"><nlm:affiliation>Department of Medical Oncology, Hospital Universitario 12 de Octubre, Madrid, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Department of Medical Oncology, Hospital Universitario 12 de Octubre, Madrid</wicri:regionArea><placeName><settlement type="city">Madrid</settlement><region nuts="2" type="region">Communauté de Madrid</region></placeName></affiliation></author><author><name sortKey="Martin Soberon, Maricruz" sort="Martin Soberon, Maricruz" uniqKey="Martin Soberon M" first="Maricruz" last="Martin-Soberon">Maricruz Martin-Soberon</name><affiliation wicri:level="3"><nlm:affiliation>Department of Medical Oncology, Hospital Universitario 12 de Octubre, Madrid, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Department of Medical Oncology, Hospital Universitario 12 de Octubre, Madrid</wicri:regionArea><placeName><settlement type="city">Madrid</settlement><region nuts="2" type="region">Communauté de Madrid</region></placeName></affiliation></author><author><name sortKey="Castellano, Daniel" sort="Castellano, Daniel" uniqKey="Castellano D" first="Daniel" last="Castellano">Daniel Castellano</name><affiliation wicri:level="3"><nlm:affiliation>Department of Medical Oncology, Hospital Universitario 12 de Octubre, Madrid, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Department of Medical Oncology, Hospital Universitario 12 de Octubre, Madrid</wicri:regionArea><placeName><settlement type="city">Madrid</settlement><region nuts="2" type="region">Communauté de Madrid</region></placeName></affiliation></author><author><name sortKey="Bourlon, Christianne" sort="Bourlon, Christianne" uniqKey="Bourlon C" first="Christianne" last="Bourlon">Christianne Bourlon</name><affiliation wicri:level="1"><nlm:affiliation>Department of Hematology and Oncology, Instituto Nacional de Ciencias Medicas y Nutrición Salvador Zubirán, Mexico City, Mexico.</nlm:affiliation><country xml:lang="fr">Mexique</country><wicri:regionArea>Department of Hematology and Oncology, Instituto Nacional de Ciencias Medicas y Nutrición Salvador Zubirán, Mexico City</wicri:regionArea><wicri:noRegion>Mexico City</wicri:noRegion></affiliation></author><author><name sortKey="De Velasco, Guillermo" sort="De Velasco, Guillermo" uniqKey="De Velasco G" first="Guillermo" last="De Velasco">Guillermo De Velasco</name><affiliation wicri:level="3"><nlm:affiliation>Department of Medical Oncology, Hospital Universitario 12 de Octubre, Madrid, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Department of Medical Oncology, Hospital Universitario 12 de Octubre, Madrid</wicri:regionArea><placeName><settlement type="city">Madrid</settlement><region nuts="2" type="region">Communauté de Madrid</region></placeName></affiliation></author><author><name sortKey="Bourlon, Maria T" sort="Bourlon, Maria T" uniqKey="Bourlon M" first="Maria T" last="Bourlon">Maria T. Bourlon</name><affiliation wicri:level="1"><nlm:affiliation>Department of Hematology and Oncology, Instituto Nacional de Ciencias Medicas y Nutrición Salvador Zubirán, Mexico City, Mexico.</nlm:affiliation><country xml:lang="fr">Mexique</country><wicri:regionArea>Department of Hematology and Oncology, Instituto Nacional de Ciencias Medicas y Nutrición Salvador Zubirán, Mexico City</wicri:regionArea><wicri:noRegion>Mexico City</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2020">2020</date><idno type="RBID">pubmed:32785928</idno><idno type="pmid">32785928</idno><idno type="doi">10.46883/ONC.2020.3408.0317</idno><idno type="wicri:Area/Main/Corpus">000702</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000702</idno><idno type="wicri:Area/Main/Curation">000702</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000702</idno><idno type="wicri:Area/Main/Exploration">000702</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Challenges of Treating a Patient With Advanced Prostate Cancer During the COVID-19 Pandemic.</title><author><name sortKey="Carril Ajuria, Lucil" sort="Carril Ajuria, Lucil" uniqKey="Carril Ajuria L" first="Lucil" last="Carril-Ajuria">Lucil Carril-Ajuria</name><affiliation wicri:level="3"><nlm:affiliation>Department of Medical Oncology, Hospital Universitario 12 de Octubre, Madrid, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Department of Medical Oncology, Hospital Universitario 12 de Octubre, Madrid</wicri:regionArea><placeName><settlement type="city">Madrid</settlement><region nuts="2" type="region">Communauté de Madrid</region></placeName></affiliation></author><author><name sortKey="Remolina Bonilla, Yuly A" sort="Remolina Bonilla, Yuly A" uniqKey="Remolina Bonilla Y" first="Yuly A" last="Remolina-Bonilla">Yuly A. Remolina-Bonilla</name><affiliation wicri:level="1"><nlm:affiliation>Department of Hematology and Oncology, Instituto Nacional de Ciencias Medicas y Nutrición Salvador Zubirán, Mexico City, Mexico.</nlm:affiliation><country xml:lang="fr">Mexique</country><wicri:regionArea>Department of Hematology and Oncology, Instituto Nacional de Ciencias Medicas y Nutrición Salvador Zubirán, Mexico City</wicri:regionArea><wicri:noRegion>Mexico City</wicri:noRegion></affiliation></author><author><name sortKey="Carretero Gonzalez, Alberto" sort="Carretero Gonzalez, Alberto" uniqKey="Carretero Gonzalez A" first="Alberto" last="Carretero-Gonzalez">Alberto Carretero-Gonzalez</name><affiliation wicri:level="3"><nlm:affiliation>Department of Medical Oncology, Hospital Universitario 12 de Octubre, Madrid, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Department of Medical Oncology, Hospital Universitario 12 de Octubre, Madrid</wicri:regionArea><placeName><settlement type="city">Madrid</settlement><region nuts="2" type="region">Communauté de Madrid</region></placeName></affiliation></author><author><name sortKey="Martin Soberon, Maricruz" sort="Martin Soberon, Maricruz" uniqKey="Martin Soberon M" first="Maricruz" last="Martin-Soberon">Maricruz Martin-Soberon</name><affiliation wicri:level="3"><nlm:affiliation>Department of Medical Oncology, Hospital Universitario 12 de Octubre, Madrid, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Department of Medical Oncology, Hospital Universitario 12 de Octubre, Madrid</wicri:regionArea><placeName><settlement type="city">Madrid</settlement><region nuts="2" type="region">Communauté de Madrid</region></placeName></affiliation></author><author><name sortKey="Castellano, Daniel" sort="Castellano, Daniel" uniqKey="Castellano D" first="Daniel" last="Castellano">Daniel Castellano</name><affiliation wicri:level="3"><nlm:affiliation>Department of Medical Oncology, Hospital Universitario 12 de Octubre, Madrid, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Department of Medical Oncology, Hospital Universitario 12 de Octubre, Madrid</wicri:regionArea><placeName><settlement type="city">Madrid</settlement><region nuts="2" type="region">Communauté de Madrid</region></placeName></affiliation></author><author><name sortKey="Bourlon, Christianne" sort="Bourlon, Christianne" uniqKey="Bourlon C" first="Christianne" last="Bourlon">Christianne Bourlon</name><affiliation wicri:level="1"><nlm:affiliation>Department of Hematology and Oncology, Instituto Nacional de Ciencias Medicas y Nutrición Salvador Zubirán, Mexico City, Mexico.</nlm:affiliation><country xml:lang="fr">Mexique</country><wicri:regionArea>Department of Hematology and Oncology, Instituto Nacional de Ciencias Medicas y Nutrición Salvador Zubirán, Mexico City</wicri:regionArea><wicri:noRegion>Mexico City</wicri:noRegion></affiliation></author><author><name sortKey="De Velasco, Guillermo" sort="De Velasco, Guillermo" uniqKey="De Velasco G" first="Guillermo" last="De Velasco">Guillermo De Velasco</name><affiliation wicri:level="3"><nlm:affiliation>Department of Medical Oncology, Hospital Universitario 12 de Octubre, Madrid, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Department of Medical Oncology, Hospital Universitario 12 de Octubre, Madrid</wicri:regionArea><placeName><settlement type="city">Madrid</settlement><region nuts="2" type="region">Communauté de Madrid</region></placeName></affiliation></author><author><name sortKey="Bourlon, Maria T" sort="Bourlon, Maria T" uniqKey="Bourlon M" first="Maria T" last="Bourlon">Maria T. Bourlon</name><affiliation wicri:level="1"><nlm:affiliation>Department of Hematology and Oncology, Instituto Nacional de Ciencias Medicas y Nutrición Salvador Zubirán, Mexico City, Mexico.</nlm:affiliation><country xml:lang="fr">Mexique</country><wicri:regionArea>Department of Hematology and Oncology, Instituto Nacional de Ciencias Medicas y Nutrición Salvador Zubirán, Mexico City</wicri:regionArea><wicri:noRegion>Mexico City</wicri:noRegion></affiliation></author></analytic><series><title level="j">Oncology (Williston Park, N.Y.)</title><idno type="ISSN">0890-9091</idno><imprint><date when="2020" type="published">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged (MeSH)</term><term>Androgen Antagonists (therapeutic use)</term><term>Androstenes (therapeutic use)</term><term>Anticoagulants (therapeutic use)</term><term>Antineoplastic Agents (therapeutic use)</term><term>Betacoronavirus (MeSH)</term><term>Bone Density Conservation Agents (therapeutic use)</term><term>Bone Neoplasms (complications)</term><term>Bone Neoplasms (drug therapy)</term><term>Bone Neoplasms (secondary)</term><term>Cancer Pain (complications)</term><term>Cancer Pain (therapy)</term><term>Coronavirus Infections (complications)</term><term>Coronavirus Infections (therapy)</term><term>Disease Progression (MeSH)</term><term>Docetaxel (therapeutic use)</term><term>Drug Combinations (MeSH)</term><term>Eligibility Determination (MeSH)</term><term>Heparin, Low-Molecular-Weight (therapeutic use)</term><term>Humans (MeSH)</term><term>Intensive Care Units (supply & distribution)</term><term>Lopinavir (therapeutic use)</term><term>Male (MeSH)</term><term>Oxygen Inhalation Therapy (MeSH)</term><term>Palliative Care (MeSH)</term><term>Pandemics (MeSH)</term><term>Pneumonia, Viral (complications)</term><term>Pneumonia, Viral (therapy)</term><term>Prostatic Neoplasms, Castration-Resistant (complications)</term><term>Prostatic Neoplasms, Castration-Resistant (drug therapy)</term><term>Prostatic Neoplasms, Castration-Resistant (pathology)</term><term>Renal Insufficiency (MeSH)</term><term>Respiratory Insufficiency (etiology)</term><term>Respiratory Insufficiency (therapy)</term><term>Reverse Transcriptase Polymerase Chain Reaction (MeSH)</term><term>Ritonavir (therapeutic use)</term><term>Severity of Illness Index (MeSH)</term><term>Zoledronic Acid (therapeutic use)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Acide zolédronique (usage thérapeutique)</term><term>Agents de maintien de la densité osseuse (usage thérapeutique)</term><term>Androstènes (usage thérapeutique)</term><term>Antagonistes des androgènes (usage thérapeutique)</term><term>Anticoagulants (usage thérapeutique)</term><term>Antinéoplasiques (usage thérapeutique)</term><term>Association médicamenteuse (MeSH)</term><term>Betacoronavirus (MeSH)</term><term>Docetaxel (usage thérapeutique)</term><term>Douleur cancéreuse (complications)</term><term>Douleur cancéreuse (thérapie)</term><term>Détermination de l'admissibilité (MeSH)</term><term>Humains (MeSH)</term><term>Héparine bas poids moléculaire (usage thérapeutique)</term><term>Indice de gravité de la maladie (MeSH)</term><term>Infections à coronavirus (complications)</term><term>Infections à coronavirus (thérapie)</term><term>Insuffisance respiratoire (thérapie)</term><term>Insuffisance respiratoire (étiologie)</term><term>Insuffisance rénale (MeSH)</term><term>Lopinavir (usage thérapeutique)</term><term>Mâle (MeSH)</term><term>Oxygénothérapie (MeSH)</term><term>Pandémies (MeSH)</term><term>Pneumopathie virale (complications)</term><term>Pneumopathie virale (thérapie)</term><term>RT-PCR (MeSH)</term><term>Ritonavir (usage thérapeutique)</term><term>Soins palliatifs (MeSH)</term><term>Sujet âgé (MeSH)</term><term>Tumeurs osseuses (complications)</term><term>Tumeurs osseuses (secondaire)</term><term>Tumeurs osseuses (traitement médicamenteux)</term><term>Tumeurs prostatiques résistantes à la castration (anatomopathologie)</term><term>Tumeurs prostatiques résistantes à la castration (complications)</term><term>Tumeurs prostatiques résistantes à la castration (traitement médicamenteux)</term><term>Unités de soins intensifs (ressources et distribution)</term><term>Évolution de la maladie (MeSH)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Androgen Antagonists</term><term>Androstenes</term><term>Anticoagulants</term><term>Antineoplastic Agents</term><term>Bone Density Conservation Agents</term><term>Docetaxel</term><term>Heparin, Low-Molecular-Weight</term><term>Lopinavir</term><term>Ritonavir</term><term>Zoledronic Acid</term></keywords><keywords scheme="MESH" qualifier="anatomopathologie" xml:lang="fr"><term>Tumeurs prostatiques résistantes à la castration</term></keywords><keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Bone Neoplasms</term><term>Cancer Pain</term><term>Coronavirus Infections</term><term>Pneumonia, Viral</term><term>Prostatic Neoplasms, Castration-Resistant</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Bone Neoplasms</term><term>Prostatic Neoplasms, Castration-Resistant</term></keywords><keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Respiratory Insufficiency</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Prostatic Neoplasms, Castration-Resistant</term></keywords><keywords scheme="MESH" qualifier="ressources et distribution" xml:lang="fr"><term>Unités de soins intensifs</term></keywords><keywords scheme="MESH" qualifier="secondaire" xml:lang="fr"><term>Tumeurs osseuses</term></keywords><keywords scheme="MESH" qualifier="secondary" xml:lang="en"><term>Bone Neoplasms</term></keywords><keywords scheme="MESH" qualifier="supply & distribution" xml:lang="en"><term>Intensive Care Units</term></keywords><keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Cancer Pain</term><term>Coronavirus Infections</term><term>Pneumonia, Viral</term><term>Respiratory Insufficiency</term></keywords><keywords scheme="MESH" qualifier="thérapie" xml:lang="fr"><term>Douleur cancéreuse</term><term>Infections à coronavirus</term><term>Insuffisance respiratoire</term><term>Pneumopathie virale</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Tumeurs osseuses</term><term>Tumeurs prostatiques résistantes à la castration</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Acide zolédronique</term><term>Agents de maintien de la densité osseuse</term><term>Androstènes</term><term>Antagonistes des androgènes</term><term>Anticoagulants</term><term>Antinéoplasiques</term><term>Docetaxel</term><term>Douleur cancéreuse</term><term>Héparine bas poids moléculaire</term><term>Infections à coronavirus</term><term>Lopinavir</term><term>Pneumopathie virale</term><term>Ritonavir</term><term>Tumeurs osseuses</term><term>Tumeurs prostatiques résistantes à la castration</term></keywords><keywords scheme="MESH" qualifier="étiologie" xml:lang="fr"><term>Insuffisance respiratoire</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Betacoronavirus</term><term>Disease Progression</term><term>Drug Combinations</term><term>Eligibility Determination</term><term>Humans</term><term>Male</term><term>Oxygen Inhalation Therapy</term><term>Palliative Care</term><term>Pandemics</term><term>Renal Insufficiency</term><term>Reverse Transcriptase Polymerase Chain Reaction</term><term>Severity of Illness Index</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Association médicamenteuse</term><term>Betacoronavirus</term><term>Détermination de l'admissibilité</term><term>Humains</term><term>Indice de gravité de la maladie</term><term>Insuffisance rénale</term><term>Mâle</term><term>Oxygénothérapie</term><term>Pandémies</term><term>RT-PCR</term><term>Soins palliatifs</term><term>Sujet âgé</term><term>Évolution de la maladie</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">A 78-year-old man had a medical history of hypertension, atrial fibrillation, chronic kidney disease, and metastatic castration-resistant prostate cancer (CRPC). He had progressed to first-line therapy for CRPC with abiraterone plus androgen-deprivation therapy (ADT) and as second-line therapy he was being treated with docetaxel, with biochemical progression in his last prostate specific antigen measurement. He was admitted to the hospital on April 2020, in the middle of the coronavirus disease 2019 (COVID-19) pandemic, because of painful bone lesions and deterioration of renal function.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32785928</PMID><DateCompleted><Year>2020</Year><Month>08</Month><Day>20</Day></DateCompleted><DateRevised><Year>2020</Year><Month>08</Month><Day>20</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0890-9091</ISSN><JournalIssue CitedMedium="Internet"><Volume>34</Volume><Issue>8</Issue><PubDate><Year>2020</Year><Month>08</Month><Day>12</Day></PubDate></JournalIssue><Title>Oncology (Williston Park, N.Y.)</Title><ISOAbbreviation>Oncology (Williston Park)</ISOAbbreviation></Journal><ArticleTitle>Challenges of Treating a Patient With Advanced Prostate Cancer During the COVID-19 Pandemic.</ArticleTitle><Pagination><MedlinePgn>317-319</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.46883/ONC.2020.3408.0317</ELocationID><Abstract><AbstractText>A 78-year-old man had a medical history of hypertension, atrial fibrillation, chronic kidney disease, and metastatic castration-resistant prostate cancer (CRPC). He had progressed to first-line therapy for CRPC with abiraterone plus androgen-deprivation therapy (ADT) and as second-line therapy he was being treated with docetaxel, with biochemical progression in his last prostate specific antigen measurement. He was admitted to the hospital on April 2020, in the middle of the coronavirus disease 2019 (COVID-19) pandemic, because of painful bone lesions and deterioration of renal function.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Carril-Ajuria</LastName><ForeName>Lucil</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Medical Oncology, Hospital Universitario 12 de Octubre, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Remolina-Bonilla</LastName><ForeName>Yuly A</ForeName><Initials>YA</Initials><AffiliationInfo><Affiliation>Department of Hematology and Oncology, Instituto Nacional de Ciencias Medicas y Nutrición Salvador Zubirán, Mexico City, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Carretero-Gonzalez</LastName><ForeName>Alberto</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Medical Oncology, Hospital Universitario 12 de Octubre, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martin-Soberon</LastName><ForeName>Maricruz</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Medical Oncology, Hospital Universitario 12 de Octubre, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Castellano</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Medical Oncology, Hospital Universitario 12 de Octubre, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bourlon</LastName><ForeName>Christianne</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Hematology and Oncology, Instituto Nacional de Ciencias Medicas y Nutrición Salvador Zubirán, Mexico City, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Velasco</LastName><ForeName>Guillermo</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Medical Oncology, Hospital Universitario 12 de Octubre, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bourlon</LastName><ForeName>Maria T</ForeName><Initials>MT</Initials><AffiliationInfo><Affiliation>Department of Hematology and Oncology, Instituto Nacional de Ciencias Medicas y Nutrición Salvador Zubirán, Mexico City, Mexico.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Oncology (Williston Park)</MedlineTA><NlmUniqueID>8712059</NlmUniqueID><ISSNLinking>0890-9091</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000726">Androgen Antagonists</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000736">Androstenes</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000925">Anticoagulants</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D050071">Bone Density Conservation Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004338">Drug Combinations</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D006495">Heparin, Low-Molecular-Weight</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C558899">lopinavir-ritonavir drug combination</NameOfSubstance></Chemical><Chemical><RegistryNumber>15H5577CQD</RegistryNumber><NameOfSubstance UI="D000077143">Docetaxel</NameOfSubstance></Chemical><Chemical><RegistryNumber>2494G1JF75</RegistryNumber><NameOfSubstance UI="D061466">Lopinavir</NameOfSubstance></Chemical><Chemical><RegistryNumber>6XC1PAD3KF</RegistryNumber><NameOfSubstance UI="D000077211">Zoledronic Acid</NameOfSubstance></Chemical><Chemical><RegistryNumber>G819A456D0</RegistryNumber><NameOfSubstance UI="C089740">abiraterone</NameOfSubstance></Chemical><Chemical><RegistryNumber>O3J8G9O825</RegistryNumber><NameOfSubstance UI="D019438">Ritonavir</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Disease" UI="C000657245">COVID-19</SupplMeshName><SupplMeshName Type="Organism" UI="C000656484">severe acute respiratory syndrome coronavirus 2</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000726" MajorTopicYN="N">Androgen Antagonists</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000736" MajorTopicYN="N">Androstenes</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000925" MajorTopicYN="N">Anticoagulants</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000970" MajorTopicYN="N">Antineoplastic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000073640" MajorTopicYN="N">Betacoronavirus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D050071" MajorTopicYN="N">Bone Density Conservation Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001859" MajorTopicYN="N">Bone Neoplasms</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000556" MajorTopicYN="N">secondary</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000072716" MajorTopicYN="N">Cancer Pain</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018352" MajorTopicYN="N">Coronavirus Infections</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000077143" MajorTopicYN="N">Docetaxel</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004338" MajorTopicYN="N">Drug Combinations</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004608" MajorTopicYN="N">Eligibility Determination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006495" MajorTopicYN="N">Heparin, Low-Molecular-Weight</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007362" MajorTopicYN="N">Intensive Care Units</DescriptorName><QualifierName UI="Q000600" MajorTopicYN="N">supply & distribution</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D061466" MajorTopicYN="N">Lopinavir</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010102" MajorTopicYN="N">Oxygen Inhalation Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010166" MajorTopicYN="Y">Palliative Care</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011024" MajorTopicYN="N">Pneumonia, Viral</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D064129" MajorTopicYN="N">Prostatic Neoplasms, Castration-Resistant</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051437" MajorTopicYN="N">Renal Insufficiency</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012131" MajorTopicYN="N">Respiratory Insufficiency</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020133" MajorTopicYN="N">Reverse Transcriptase Polymerase Chain Reaction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019438" MajorTopicYN="N">Ritonavir</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000077211" MajorTopicYN="N">Zoledronic Acid</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>8</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>8</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>8</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32785928</ArticleId><ArticleId IdType="doi">10.46883/ONC.2020.3408.0317</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Espagne</li><li>Mexique</li></country><region><li>Communauté de Madrid</li></region><settlement><li>Madrid</li></settlement></list><tree><country name="Espagne"><region name="Communauté de Madrid"><name sortKey="Carril Ajuria, Lucil" sort="Carril Ajuria, Lucil" uniqKey="Carril Ajuria L" first="Lucil" last="Carril-Ajuria">Lucil Carril-Ajuria</name></region><name sortKey="Carretero Gonzalez, Alberto" sort="Carretero Gonzalez, Alberto" uniqKey="Carretero Gonzalez A" first="Alberto" last="Carretero-Gonzalez">Alberto Carretero-Gonzalez</name><name sortKey="Castellano, Daniel" sort="Castellano, Daniel" uniqKey="Castellano D" first="Daniel" last="Castellano">Daniel Castellano</name><name sortKey="De Velasco, Guillermo" sort="De Velasco, Guillermo" uniqKey="De Velasco G" first="Guillermo" last="De Velasco">Guillermo De Velasco</name><name sortKey="Martin Soberon, Maricruz" sort="Martin Soberon, Maricruz" uniqKey="Martin Soberon M" first="Maricruz" last="Martin-Soberon">Maricruz Martin-Soberon</name></country><country name="Mexique"><noRegion><name sortKey="Remolina Bonilla, Yuly A" sort="Remolina Bonilla, Yuly A" uniqKey="Remolina Bonilla Y" first="Yuly A" last="Remolina-Bonilla">Yuly A. Remolina-Bonilla</name></noRegion><name sortKey="Bourlon, Christianne" sort="Bourlon, Christianne" uniqKey="Bourlon C" first="Christianne" last="Bourlon">Christianne Bourlon</name><name sortKey="Bourlon, Maria T" sort="Bourlon, Maria T" uniqKey="Bourlon M" first="Maria T" last="Bourlon">Maria T. Bourlon</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidSeniorV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000825 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000825 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= CovidSeniorV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:32785928
|texte= Challenges of Treating a Patient With Advanced Prostate Cancer During the COVID-19 Pandemic.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:32785928" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a CovidSeniorV1
| This area was generated with Dilib version V0.6.37. |  |